Ibrutinib plus lenalidomide and rituximab has promising activity in relapsed/refractory non–germinal center B-cell–like DLBCL von Goy, Andre, Ramchandren, Radhakrishnan, Ghosh, Nilanjan, Munoz, Javier, Morgan, David S., Dang, Nam H., Knapp, Mark, Delioukina, Maria, Kingsley, Edwin, Ping, Jerry, Beaupre, Darrin M., Neuenburg, Jutta K., Ruan, Jia

Volltext

Single-dose, subcutaneous recombinant phenylalanine ammonia lyase conjugated with polyethylene glycol in adult patients with phenylketonuria: an open-label, multicentre, phase 1 do... von Longo, Nicola, MD, Harding, Cary O, MD, Burton, Barbara K, MD, Grange, Dorothy K, MD, Vockley, Jerry, MD, Wasserstein, Melissa, MD, Rice, Gregory M, MD, Dorenbaum, Alejandro, MD, Neuenburg, Jutta K, MD, Musson, Donald G, PhD, Gu, Zhonghua, PhD, Sile, Saba, MD

Volltext

Concurrent ibrutinib plus venetoclax in relapsed/refractory mantle cell lymphoma: the safety run-in of the phase 3 SYMPATICO study von Wang, Michael, Ramchandren, Radhakrishnan, Chen, Robert, Karlin, Lionel, Chong, Geoffrey, Jurczak, Wojciech, Wu, Ka Lung, Bishton, Mark, Collins, Graham P, Eliadis, Paul, Peyrade, Frédéric, Lee, Yihua, Eckert, Karl, Neuenburg, Jutta K, Tam, Constantine S

Volltext

Safety and activity of BTK inhibitor ibrutinib combined with ofatumumab in chronic lymphocytic leukemia: a phase 1b/2 study von Jaglowski, Samantha M., Jones, Jeffrey A., Nagar, Veena, Flynn, Joseph M., Andritsos, Leslie A., Maddocks, Kami J., Woyach, Jennifer A., Blum, Kristie A., Grever, Michael R., Smucker, Kelly, Ruppert, Amy S., Heerema, Nyla A., Lozanski, Gerard, Stefanos, Mona, Munneke, Brian, West, Jamie-Sue, Neuenburg, Jutta K., James, Danelle F., Hall, Nathan, Johnson, Amy J., Byrd, John C.

Volltext

The combination of ibrutinib and rituximab demonstrates activity in first‐line follicular lymphoma von Fowler, Nathan H., Nastoupil, Loretta, De Vos, Sven, Knapp, Mark, Flinn, Ian W., Chen, Robert, Advani, Ranjana H., Bhatia, Sumeet, Martin, Peter, Mena, Raul, Davis, Richard Eric, Neelapu, Sattva S., Eckert, Karl, Ping, Jerry, Co, Melannie, Beaupre, Darrin M., Neuenburg, Jutta K., Palomba, M. Lia

Volltext

Mapping gene associations in human mitochondria using clinical disease phenotypes von Scharfe, Curt, Lu, Henry Horng-Shing, Neuenburg, Jutta K, Allen, Edward A, Li, Guan-Cheng, Klopstock, Thomas, Cowan, Tina M, Enns, Gregory M, Davis, Ronald W

Volltext

The iR2 regimen (ibrutinib plus lenalidomide and rituximab) for relapsed/refractory DLBCL: a multicentre, non-randomised, open-label phase 2 study von Ramchandren, Radhakrishnan, Johnson, Peter, Ghosh, Nilanjan, Ruan, Jia, Ardeshna, Kirit M., Johnson, Roderick, Verhoef, Gregor, Cunningham, David, de Vos, Sven, Kassam, Shireen, Fayad, Luis, Radford, John, Bailly, Sarah, Offner, Fritz, Morgan, David, Munoz, Javier, Ping, Jerry, Szafer-Glusman, Edith, Eckert, Karl, Neuenburg, Jutta K., Goy, Andre

Volltext

HIV-related neuropathology, 1985 to 1999: Rising prevalence of HIV encephalopathy in the era of highly active antiretroviral therapy von NEUENBURG, Jutta K, BRODT, Hans R, HERNDIER, Brian G, BICKEL, Markus, BACCHETTI, Peter, PRICE, Richard W, GRANT, Robert M, SCHLOTE, Wolfgang

Volltext

T-Cell Activation and Memory Phenotypes in Cerebrospinal Fluid During HIV Infection von Neuenburg, Jutta K, Cho, Tracey A, Nilsson, Annelie, Bredt, Barry M, Hebert, Samuel J, Grant, Robert M, Price, Richard W

Volltext

Activity and Tolerability of Ibrutinib in Combination With Ofatumumab in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) von Jaglowski, Samantha M., MD, MPH, Jones, Jeffrey A., MD, MPH, Flynn, Joseph M., DO, MPH, Andritsos, Leslie A., MD, Maddocks, Kami J., MD, Woyach, Jennifer A., MD, Blum, Kristie A., MD, Grever, Michael R., MD, Geyer, Susan Michelle, PhD, Heerema, Nyla A., PhD, Lozanski, Gerard, MD, Stefanos, Mona, BS, Hall, Nathan, MD, PhD, Nagar, Veena, MD, Munneke, Brian, PhD, West, Jamie-Sue, Neuenburg, Jutta K., MD, PhD, James, Danelle F., MD, MAS, Johnson, Amy J., PhD, Byrd, John C., MD

Volltext

Enrichment of activated monocytes in cerebrospinal fluid during antiretroviral therapy von NEUENBURG, Jutta K, FURLAN, Scott, BACCHETTI, Peter, PRICE, Richard W, GRANT, Robert M

Volltext

Ibrutinib Combined with Venetoclax in Patients with Relapsed/Refractory Mantle Cell Lymphoma: Primary Analysis Results from the Randomized Phase 3 Sympatico Study von Wang, Michael, Jurczak, Wojciech, Trněný, Marek, Belada, David, Wrobel, Tomasz, Ghosh, Nilanjan, Keating, Mary-Margaret, van Meerten, Tom, Fernandez Alvarez, Ruben, von Keudell, Gottfried, Thieblemont, Catherine, Peyrade, Frederic, Andre, Marc, Hoffmann, Marc, Szafer Glusman, Edith, Lin, Jennifer, Dean, James P., Neuenburg, Jutta K., Tam, Constantine S.

Volltext

MCL-129: First-Line Ibrutinib Plus Venetoclax in MCL for Older Patients or Those with a TP53 Mutation: Ongoing Open-Label Arm of the PCYC-1143 Phase 3 SYMPATICO Study von Wang, Michael L., Jurczak, Wojciech, Eckert, Karl, Lin, Jennifer, Neuenburg, Jutta, Tam, Constantine

Volltext

Ibrutinib Plus Venetoclax in Patients With Relapsed/Refractory Mantle Cell Lymphoma: Results From the Safety Run-In Period of the Phase 3 Sympatico Study von Tam, Constantine S., Ramchandren, Radhakrishnan, Chen, Robert, Karlin, Lionel, Chong, Geoffrey, Jurczak, Wojciech, Wu, Ka Lung, Bishton, Mark, Collins, Graham P., Eliadis, Paul, Peyrade, Frédéric, Szafer-Glusman, Edith, Lee, Yihua, Eckert, Karl, Neuenburg, Jutta K., Wang, Michael

Volltext

HIV-Producing T Cells in Cerebrospinal Fluid von Neuenburg, Jutta K, Sinclair, Elizabeth, Nilsson, Annelie, Kreis, Christophe, Bacchetti, Peter, Price, Richard W, Grant, Robert M

Volltext

Efficacy and Safety of Ibrutinib Plus Venetoclax in Patients With Mantle Cell Lymphoma (MCL) and TP53 Mutations in the SYMPATICO Study von Jurczak, Wojciech, Wang, Michael, Trneny, Marek, Belada, David, Wrobel, Tomasz, Ghosh, Nilanjan, Keating, Mary-Margaret, van Meerten, Tom, Fernandez Alvarez, Ruben, von Keudell, Gottfried, Thieblemont, Catherine, Peyrade, Frederic, Andre, Marc, Hoffmann, Marc, Naganuma, Maoko, Szafer-Glusman, Edith, Lin, Jennifer, Dean, James P., Neuenburg, Jutta K., Tam, Constantine S.

Volltext

MCL-058 Efficacy and Safety of Ibrutinib Plus Venetoclax in Patients With Mantle Cell Lymphoma (MCL) and TP53 Mutations in the SYMPATICO Study von Jurczak, Wojciech, Wang, Michael, Trneny, Marek, Belada, David, Wrobel, Tomasz, Ghosh, Nilanjan, Keating, Mary-Margaret, van Wrobel, Tom, Fernandez Alvarez, Ruben, von Keudell, Gottfried, Thieblemont, Catherine, Peyrade, Frederic, Andre, Marc, Hoffmann, Marc, Naganuma, Maoko, Szafer-Glusman, Edith, Lin, Jennifer, Dean, James P., Neuenburg, Jutta K., Tam, Constantine S.

Volltext

Phase 2 Results of the iR2 Regimen (Ibrutinib, Lenalidomide, and Rituximab) in Patients with Relapsed/Refractory (R/R) Non-Germinal Center B Cell-like (Non-GCB) Diffuse Large B-Cel... von Ramchandren, Radhakrishnan, Johnson, Peter, Ghosh, Nilanjan, Ruan, Jia, Ardeshna, Kirit M., Johnson, Roderick, Verhoef, Gregor, Cunningham, David, de Vos, Sven, Kassam, Shireen, Fayad, Luis, Radford, John, Bailly, Sarah, Offner, Fritz, Morgan, David, Munoz, Javier, Ping, Jerry, Kwei, Kevin, Eckert, Karl, Neuenburg, Jutta K., Goy, Andre

Volltext

Ibrutinib Enhances the Activity of Anti-CD20 Antibodies in an MCL Mouse Model: Effect of Drug at Clinically Relevant Concentrations on ADCC and ADCP von Ng, Patrick P., Lu, Daniel K., Sukbuntherng, Juthamas, Neuenburg, Jutta K., James, Danelle F., Chang, Betty Y.

Volltext

The iR2 Regimen(Ibrutinib, Lenalidomide, and Rituximab) Is Active with a Manageable Safety Profile in Patients with Relapsed/Refractory Non-Germinal Center-like Diffuse Large B-Cel... von Ramchandren, Radhakrishnan, Johnson, Peter, Ghosh, Nilanjan, Ruan, Jia, Ardeshna, Kirit M., Johnson, Roderick, Verhoef, Gregor, Cunningham, David, de Vos, Sven, Kassam, Shireen, Fayad, Luis, Radford, John, Bailly, Sarah, Offner, Fritz, Morgan, David, Munoz, Javier, Ping, Jerry, Co, Melannie, Neuenburg, Jutta K., Goy, Andre

Volltext